These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 9126145)

  • 1. New strategies with dopaminergic drugs: modified formulations of levodopa and novel agonists.
    Goetz CG
    Exp Neurol; 1997 Mar; 144(1):17-20. PubMed ID: 9126145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopaminergic agonists in the treatment of Parkinson's disease.
    Goetz CG; Diederich NJ
    Neurol Clin; 1992 May; 10(2):527-40. PubMed ID: 1350052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease.
    Olanow CW; Obeso JA; Stocchi F
    Nat Clin Pract Neurol; 2006 Jul; 2(7):382-92. PubMed ID: 16932589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New pharmacologic strategies for the treatment of Parkinson disease].
    Tolosa E; Molinuevo JL; Valldeoriola F; Pastor P
    Neurologia; 1999 May; 14 Suppl 1():46-53. PubMed ID: 10377729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel pharmacological targets for the treatment of Parkinson's disease.
    Schapira AH; Bezard E; Brotchie J; Calon F; Collingridge GL; Ferger B; Hengerer B; Hirsch E; Jenner P; Le Novère N; Obeso JA; Schwarzschild MA; Spampinato U; Davidai G
    Nat Rev Drug Discov; 2006 Oct; 5(10):845-54. PubMed ID: 17016425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pathological gambling behavior in a patient with Parkinson's disease treated with levodopa and bromocriptine].
    Montastruc JL; Schmitt L; Bagheri H
    Rev Neurol (Paris); 2003 Apr; 159(4):441-3. PubMed ID: 12773874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parkinson's disease.
    Wolters EC; Calne DB
    CMAJ; 1989 Mar; 140(5):507-14. PubMed ID: 2563667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of dopamine agonists in Parkinson's disease: an update.
    Bonuccelli U; Pavese N
    Expert Rev Neurother; 2007 Oct; 7(10):1391-9. PubMed ID: 17939774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Antiparkinsonian drugs].
    Rascol A; Montastruc JL; Rascol O
    Rev Prat; 1989 Mar; 39(8):663-9. PubMed ID: 2567051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pergolide and Parkinson's disease: new preparation. No clear benefit.
    Prescrire Int; 2000 Dec; 9(50):177-9. PubMed ID: 11475497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relating mode of action to clinical practice: dopaminergic agents in Parkinson's disease.
    Riederer P; Gerlach M; Müller T; Reichmann H
    Parkinsonism Relat Disord; 2007 Dec; 13(8):466-79. PubMed ID: 17919963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Diagnosis and therapy of Parkinson's disease].
    Wittstock M; Benecke R
    MMW Fortschr Med; 2005 May; 147 Spec No 2():28-31. PubMed ID: 15968869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Continuous dopaminergic stimulation, pulsatile dopaminergic stimulation].
    Destée A; Bordet R
    Rev Neurol (Paris); 2002 Dec; 158 Spec no 1():S69-82. PubMed ID: 12690666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Drug therapy in Parkinson's disease].
    van Hilten JJ; Roos RA
    Ned Tijdschr Geneeskd; 1999 Jan; 143(5):234-40. PubMed ID: 10086151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Should levodopa be used anymore?
    Zegers de Beyl D
    Acta Neurol Belg; 2002 Dec; 102(4):163-6. PubMed ID: 12534242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing long-term therapy for Parkinson disease: levodopa, dopamine agonists, and treatment-associated dyskinesia.
    Stacy M; Galbreath A
    Clin Neuropharmacol; 2008; 31(1):51-6. PubMed ID: 18303491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continuous dopaminergic stimulation and novel formulations of dopamine agonists.
    Stocchi F
    J Neurol; 2011 May; 258(Suppl 2):S316-22. PubMed ID: 21560062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists.
    Kondo T
    J Neurol; 2002 Sep; 249 Suppl 2():II25-9. PubMed ID: 12375060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conversion from dopamine agonists to pramipexole. An open-label trial in 227 patients with advanced Parkinson's disease.
    Linazasoro G;
    J Neurol; 2004 Mar; 251(3):335-9. PubMed ID: 15015015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Updates in practical neurology--I. The principles of modern levodopa therapy in Parkinson's disease].
    Klivényi P; Vécsei L
    Ideggyogy Sz; 2007 Jan; 60(1-2):61-4. PubMed ID: 17432097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.